A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer

被引:13
|
作者
Clement-Duchene, Christelle [1 ,2 ]
Natale, Ronald B. [3 ]
Jahan, Thierry [4 ]
Krupitskaya, Yelena [1 ]
Osarogiagbon, Raymond [5 ]
Sanborn, Rachel E. [6 ]
Bernstein, Eric D. [6 ]
Dudek, Arkadiusz Z. [7 ]
Latz, Jane E. [8 ]
Shi, Peipei [8 ]
Wakelee, Heather A. [1 ]
机构
[1] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA
[2] CHU Nancy, Chest Dept, Nancy, France
[3] Cedars Sinai Canc Ctr, Los Angeles, CA USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Univ Tennessee, Memphis, TN USA
[6] Providence Portland Med Ctr, Portland, OR USA
[7] Univ Minnesota, Minneapolis, MN USA
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
NSCLC; Erlotinib; Enzastaurin; PROTEIN-KINASE-C; BETA INHIBITOR; PKC-BETA; SELECTIVE INHIBITOR; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; DOSE-ESCALATION; SOLID TUMORS; TRIAL; CHEMOTHERAPY;
D O I
10.1016/j.lungcan.2012.06.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Regardless of epidermal growth factor receptor (EGFR) mutation status, erlotinib improves survival for patients with advanced non-small cell lung cancer (NSCLC) after one or more chemotherapy regimens. Enzastaurin is an oral serine/threonine kinase inhibitor. This phase II study was designed to evaluate the efficacy and safety of erlotinib and enzastaurin in NSCLC, a combination with promise to overcome EGFR resistance based on preclinical models. Methods: Eligible patients with advanced NSCLC (IIIB or IV) who had failed one or two prior systemic treatment regimen(s) were enrolled and received erlotinib 150 mg/day and enzastaurin 500 mg/day (after a 1125-mg loading dose on day 1, cycle 1), both orally in 28-day cycles. The primary endpoint was progression-free survival (PFS). Results: From January 2008 to July 2009,49 patients were enrolled: 29(59%) men and 20(41%) women; 8 (16%) were non-smokers. The median PFS was 1.7 months (one-sided 90% Cl: 1.5-NA) and median overall survival (OS) was 8.3 months (95% CI: 5.3-14.3). Five patients had partial response, for an overall response rate of 10.2%; the disease control rate was 30.6% (responders + 10 patients with stable disease). Grade 3-4 drug-related adverse events in >= 5% of patients were diarrhea, acne, and nausea. One possibly drug-related death due to interstitial lung disease occurred during the study. Conclusions: In previously treated, unselected, advanced NSCLC patients, the addition of enzastaurin to erlotinib did not improve PFS, response, or OS compared with historical data of single-agent erlotinib, but was well tolerated. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 50 条
  • [21] Randomized phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Garon, E. B.
    Dubinett, S. M.
    Hosmer, W.
    Reckamp, K. L.
    Kabbinavar, F. F.
    Goodglick, L.
    Marquez-Garban, D. C.
    Stabile, L. P.
    Siegfried, J.
    Pietras, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
    Gerena-Lewis, Margie
    Crawford, Jeffrey
    Bonomi, Philip
    Maddox, Ann Marie
    Hainsworth, John
    McCune, David E.
    Shukla, Rakesh
    Zeigler, Haoyue
    Hurtubise, Paul
    Chowdhury, Tracy R.
    Fletcher, Brandon
    Dyehouse, Karyn
    Ghalie, Richard
    Jazieh, Abdul R.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (03): : 269 - 273
  • [23] A single arm phase 2 study of enzastaurin in combination with erlotinib, both administered orally daily, to patients with advanced non-small cell lung cancer (NSCLC)
    Wakelee, Heather A.
    Dubey, Sarita
    Krupitskaya, Yelena
    Osarogiagbon, Raymond U.
    Sanborn, Rachel E.
    Bernstein, Eric D.
    Dudek, Arkadiusz Z.
    Latz, Jane E.
    Yuan, Zheng
    Natale, Ronald B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S445 - S445
  • [24] A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer
    Komiya, Takefumi
    Memmott, Regan M.
    Blumenthal, Gideon M.
    Bernstein, Wendy
    Ballas, Marc S.
    De Chowdhury, Roopa
    Chun, Guinevere
    Peer, Cody J.
    Figg, William D.
    Liewehr, David J.
    Steinberg, Seth M.
    Giaccone, Giuseppe
    Szabo, Eva
    Kawabata, Shigeru
    Tsurutani, Junji
    Rajan, Arun
    Dennis, Phillip A.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 247 - +
  • [25] A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer
    Heist, Rebecca Suk
    Fidias, Panos
    Huberman, Mark
    Ardman, Blair
    Sequist, Lecia V.
    Temel, Jennifer S.
    Lynch, Thomas J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (10) : 1153 - 1158
  • [26] Initial safety and efficacy results of erlotinib in previously treated patients with advanced non-small cell lung cancer
    Zhou, S.
    Zhou, C.
    Yan, L.
    Xu, Q.
    Xu, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Phase II pharmacodynamic trial of erlotinib in previously treated patients with advanced non-small-cell lung cancer (NSCLC):: Study results
    Felip, Enriqueta
    Rojo, Frederico
    Reck, Martin
    Heller, Astrid
    Klughammer, Barbara
    Maacke, Heiko
    Mocks, Joachim
    Brennscheidt, Ulrich
    Gatzemeier, Ulrich
    Baselga, Jose
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 235 - 235
  • [28] Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study
    Giaccone, Giuseppe
    Ruiz, Marielle Gallegos
    Le Chevalier, Thierry
    Thatcher, Nick
    Smit, Egbert
    Rodriguez, Jose Antonio
    Janne, Pasi
    Oulid-Aissa, Dalila
    Soria, Jean-Charles
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6049 - 6055
  • [29] Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
    Kim, Young Saing
    Cho, Eun Kyung
    Woo, Hyun Sun
    Hong, Junshik
    Ahn, Hee Kyung
    Park, Inkeun
    Sym, Sun Jin
    Kyung, Sun Young
    Kang, Shin Myung
    Park, Jeong-Woong
    Jeong, Sung Hwan
    Park, Jinny
    Lee, Jae Hoon
    Shin, Dong Bok
    [J]. CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 80 - 87
  • [30] Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    S Novello
    G V Scagliotti
    R Rosell
    M A Socinski
    J Brahmer
    J Atkins
    C Pallares
    R Burgess
    L Tye
    P Selaru
    E Wang
    R Chao
    R Govindan
    [J]. British Journal of Cancer, 2009, 101 : 1543 - 1548